CIBC Asset Management Inc purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,490 shares of the biotechnology company’s stock, valued at approximately $220,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in UTHR. Quantbot Technologies LP lifted its stake in United Therapeutics by 537.3% in the third quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 822 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new position in United Therapeutics in the third quarter valued at approximately $156,000. SeaCrest Wealth Management LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $178,000. HL Financial Services LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $217,000. Finally, Toronto Dominion Bank lifted its stake in United Therapeutics by 244.7% in the third quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 1,351 shares in the last quarter.
Shares of United Therapeutics Co. (UTHR) opened at $136.92 on Thursday. United Therapeutics Co. has a fifty-two week low of $112.01 and a fifty-two week high of $169.89. The stock has a market cap of $5,920.00, a P/E ratio of 12.07 and a beta of 1.26.
A number of research analysts have weighed in on UTHR shares. TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a research note on Friday, December 15th. ValuEngine lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 2nd. Zacks Investment Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price target on the stock in a research note on Monday, January 15th. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, Cowen reaffirmed a “hold” rating and issued a $129.00 price target on shares of United Therapeutics in a research note on Friday, October 27th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $140.27.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2018/02/15/cibc-asset-management-inc-invests-220000-in-united-therapeutics-co-uthr-stock.html.
United Therapeutics Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.